As a reminder, COMP005 enrolled 258 patients with treatment-resistant depression (TRD) to receive either a 25 mg dose of the company's psilocybin candidate (COMP360) or inert placebo.
As a reminder, COMP005 enrolled 258 patients with treatment-resistant depression (TRD) to receive either a 25 mg dose of the company's psilocybin candidate (COMP360) or inert placebo.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
As a reminder, COMP005 enrolled 258 patients with treatment-resistant depression (TRD) to receive either a 25 mg dose of the company's psilocybin candidate (COMP360) or inert placebo.
Open the app view to save this story, compare related coverage, and continue from the same source.